Volume 15, Issue 2 (2023)                   Iran J War Public Health 2023, 15(2): 115-121 | Back to browse issues page

Print XML PDF HTML Full-Text (HTML)


History

Rights and permissions
1- Department of Pathological Analyses, Faculty of Science, Kufa University, AL-Najaf AL-Ashraf, Iraq
* Corresponding Author Address: Department of Pathological Analyses, Faculty of Science, Kufa University, AL-Najaf AL-Ashraf, Iraq. (ruaas.fahad@uokufa.edu.iq)
Abstract   (892 Views)
Aims: Infection is one of the most important complications of neutropenia and contributes to the high rate of morbidity and mortality. This study aimed to investigate some bacterial and fungal infections in cancer patients with neutropenia.
Materials & Methods: 110 specimens from 10 normal humans as a control group and 100 specimens from neutropenic cancer patients were collected. The ELISA technique was used to assess the presence of neutropenia in patients. The diagnosis of bacterial infections was based on the bacteriological culture of isolated specimens (blood, sputum, and urine) and biochemical test, then Vitek-2 Compact.
Findings: 60 specimens (60%) contained an infection. 44 samples (73.3%) had positive blood cultures, consisting of 25 (41.6%) in leukemia patients and 19 (31.7%) in breast cancer patients. 6 samples (10.0%) of bladder cancer patients had positive urine cultures. Positive sputum was seen in 10 samples (16.7%) of patients with lung cancer, while the cultures of 40 samples (40.0%) were negative. Ten E. coli (16.7%) was in patients with leukemia and bladder cancer, 15 Pseudomonas aeruginosa (25.0%) in patients with breast cancer and leukemia, and 25 Klebsiella pneumonia (41.7%) in the patients with leukemia, breast cancer, and bladder cancer. However, samples from patients with lung cancer contained 4 coagulase-positive Staphylococci (6.7%) and 6 Streptococcus pneumoniae (10.0%).
Conclusion: Neutropenia is more common in leukemic patients. Gram-negative bacteria are the greatest public bacteria isolated in the patients. Klebsiella pneumonia and Streptococcus pneumonia are the most common Gram-positive bacteria. All types of bacteria are resistant to most antibiotics.
 
Keywords:

References
1. Rosales C. Neutrophil: a cell with many roles in inflammation or several cell types? Front Physiol. 2018;9:113. [Link] [DOI:10.3389/fphys.2018.00113]
2. Boxer L, Dale DC. Neutropenia: Causes and consequences. Semin Hematol. 2002;39(2):75-81. [Link] [DOI:10.1053/shem.2002.31911]
3. Uribe-Querol E, Rosales C. Neutrophils in cancer: two sides of the same coin. J Immunol Res. 2015;2015:983698. [] [DOI:10.1155/2015/983698]
4. Lustberg MB. Management of neutropenia in cancer patients. Clin Adv Hematol Oncol. 2012;10(12):825-6. [Link]
5. Zaimy MA, Saffarzadeh N, Mohammadi A, Pourghadamyari H, Izadi P, Sarli A, et al. New methods in the diagnosis of cancer and gene therapy of cancer based on nanoparticles. Cancer Gene Ther. 2017;24(6):233-43. [Link] [DOI:10.1038/cgt.2017.16]
6. Hausman DM. What is cancer? Perspect Biol Med. 2019;62(4):778-84. [Link] [DOI:10.1353/pbm.2019.0046]
7. Zhou S, Gravekamp C, Bermudes D, Liu K. Tumour-targeting bacteria engineered to fight cancer. Nat Rev Cancer. 2018;18(12):727-43. [Link] [DOI:10.1038/s41568-018-0070-z]
8. Debela DT, Muzazu SG, Heraro KD, Ndalama MT, Mesele BW, Haile DC, et al. New approaches and procedures for cancer treatment: current perspectives. SAGE Open Med. 2021;9:20503121211034370. [Link] [DOI:10.1177/20503121211034366]
9. Cassidy T, Humphries AR, Craig M, Mackey MC. Characterizing chemotherapy-induced neutropenia and monocytopenia through mathematical modelling. Bull Math Biol. 2020;82(8):104. [Link] [DOI:10.1007/s11538-020-00777-0]
10. Zhao J. Cancer stem cells and chemo resistance: The smartest survives the raid. Pharmacol Ther. 3016;160:145-58. [Link] [DOI:10.1016/j.pharmthera.2016.02.008]
11. Lyman GH, Delgado DJ. Risk and timing of hospitalization for febrile neutropenia in patients receiving CHOP, CHOP‐R, or CNOP chemotherapy for intermediate‐grade non‐Hodgkin lymphoma. Cancer. 2003;98(11):2402-9. [Link] [DOI:10.1002/cncr.11827]
12. Swati M, Gita N, Sujata B, Farah J, Preeti M. Microbial etiology of febrile neutropenia. Indian J Hematol Blood Transfus. 2010;26(2):49-55. [Link] [DOI:10.1007/s12288-010-0029-z]
13. Taplitz RA, Kennedy EB, Bow EJ, Crews J, Gleason C, Hawley DK, et al. Outpatient management of fever and neutropenia in adults treated for malignancy: American Society of Clinical Oncology and Infectious Diseases Society of America Clinical Practice Guideline Update. J Clin Oncol. 2018;36(14):1443-53. [Link] [DOI:10.1200/JCO.2017.77.6211]
14. Carmona-Bayonas A, Jimenez-Fonseca P, Virizuela Echaburu J, Antonio M, Font C, Biosca M, et al. Prediction of serious complications in patients with seemingly stable febrile neutropenia: validation of the clinical index of stable febrile neutropenia in a prospective cohort of patients from the FINITE study. J Clin Oncol. 2015;33(5):465-71. [Link] [DOI:10.1200/JCO.2014.57.2347]
15. Basu SK, Fernandez ID, Fisher SG, Asselin BL, Lyman GH. Length of stay and mortality associated with febrile neutropenia among children with cancer. J Clin Oncol. 2005;23(31):7958-66. [Link] [DOI:10.1200/JCO.2005.01.6378]
16. Billote KP, Mendoza MY, Baylon HG. Infections in febrile neutropenia and possible prognostic factors associated with mortality. Philip J Microbiol Infect Dis. 1997;26(2):55-9. [Link]
17. Bodey GP. Unusual presentations of infection in neutropenic patients. Int J Antimicrob Agents. 2000;16(2):93-5. [Link] [DOI:10.1016/S0924-8579(00)00241-7]
18. Gustinetti G, Mikulska M. Bloodstream infections in neutropenic cancer patients: a practical update. Virulence. 2019;7(3):280-97. [Link] [DOI:10.1080/21505594.2016.1156821]
19. Joudeh N, Sawafta E, Abu Taha A, Hamed Allah M, Amer R, Odeh RY, et al. Epidemiology and source of infection in cancer patients with febrile neutropenia: an experience from a developing country. BMC Infect Dis. 2023;23(1):106. [Link] [DOI:10.1186/s12879-023-08058-6]
20. Bennett JE, Dolin R, Blaser MJ, editors. Mandell, Douglas, and Bennett's principles and practice of infectious diseases. 8th Edition. Volume 2. Philadelphia: Elsevier; 2015. [Link]
21. Donowitz GR, Maki DG, Crnich CJ, Pappas PG, Rolston KVI. Infections in the neutropenic patient- New views of an old problem. Hematol Am Soc Hematol Educ Program. 2001;2001(1):113-9. [Link] [DOI:10.1182/asheducation-2001.1.113]
22. Cortés JA, Cuervo S, Gómez CA, Bermúdez D, Martinez T, Arroyo P. Febrile neutropenia in the tropics: A description of clinical and microbiological findings and their impact on inappropriate therapy currently used at an oncological reference center in Colombia. Biomedica. 2013;33(1):70-7. [Link] [DOI:10.7705/biomedica.v33i1.815]
23. Bucaneve G, Micozzi A, Menichetti F, Martino P, Dionisi MS, Martinelli G, et al. Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia. New Engl J Med. 2005;353(10):977-87. doi:10.1056/NEJMoa044097. [Link] [DOI:10.1056/NEJMoa044097]
24. MacFaddin JF. Biochemical tests for identification of medical bacteria. 3rd Edition. Philadelphia: Jones & Bartlett Learning; 2000 [Link]
25. Thinggaard AB, Liposits G, Fristrup N. Dealing with pre-existing chronic neutropenia in cancer patients-considerations and consequences in the clinical praxis. Ecancermedicalscience. 2020;14:1131. [Link] [DOI:10.3332/ecancer.2020.1131]
26. Averin A, Silvia A, Lamerato L, Richert-Boe K, Kaur M, Sundaresan D, et al. Risk of chemotherapy-induced febrile neutropenia in patients with metastatic cancer not receiving granulocyte colony-stimulating factor prophylaxis in US clinical practice. Support Care Cancer. 2021;29(4):2179-86. [Link] [DOI:10.1007/s00520-020-05715-3]
27. Khalil ZK. Infectious Causes of diarrhea among neutropenic children. Al-Kindy Coll Med J. 2018;14(1):64-7. [Link] [DOI:10.47723/kcmj.v14i1.21]
28. Lim JJ, Grinstein S, Roth Z. Diversity and versatility of phagocytosis: roles in innate immunity, tissue remodeling, and homeostasis. Front Cell Infect Microbiol. 2017;7:191. [Link] [DOI:10.3389/fcimb.2017.00191]
29. Buyukberber N, Buyukberber S, Sevinc A, Camci C. Cytokine concentrations are not predictive of bacteremia in febrile neutropenic patients. Med Oncol. 2009;26(1):55-61. [Link] [DOI:10.1007/s12032-008-9081-z]
30. Rosenzweig SD, Holland SM. Recent insights into the pathobiology of innate immune deficiencies. Curr Allergy Asthma Rep. 2011;11(5):369-77. [Link] [DOI:10.1007/s11882-011-0212-9]
31. Holland T, Fowler Jr VG, Shelburne III SA. Invasive gram-positive bacterial infection in cancer patients. Clin Infect Dis. 2014;59(suppl 5):S331-4. [Link] [DOI:10.1093/cid/ciu598]
32. Shabaa RA. Prevalence evaluation of Streptococcus pneumoniae in neutropenic cancer patients. Iraqi J Biotechnol. 2017;16(3). [Link]
33. Yadegarynia D, Fatemi A, Mahdizadeh M, Movahhed RK, Alizadeh MA. Current spectrum of bacterial infections in patients with nosocomial fever and neutropenia. Caspian J Intern Med. 2013;4(3):698-701. [Link]
34. Lucas AJ, Olin JL, Coleman MD. Management and preventive measures for febrile neutropenia. Pharm Ther. 2018;43(4):228-32. [Link]
35. Al-Zubaidy AS, Jumaah SS, Radhi QR. Bacteriological diagnosis of febrile neutropenia in oncology teaching hospital. Iraqi Postgrad Med J. 2019;18(1):37-42. [Link] [DOI:10.33899/ijvs.2019.153875]
36. Al-Zubaidy AS, Jumaah SS, Radhi QR. Bacteriological study of febrile neutropenia in patients with hematological malignancies in Baghdad Teaching Hospital. Iraqi Postgrad Med J. 2020;19(1):68-73. [Link]
37. Zimmer AJ, Freifeld AG. Optimal management of neutropenic fever in patients with cancer. J Oncol Pract. 2019;15(1):19-24. [Link] [DOI:10.1200/JOP.18.00269]
38. Patterson TF, Thompson III GR, Denning DW, Fishman JA, Hadley S, Herbrecht R, et al. Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis. 2016;63(4):e1-60. [Link] [DOI:10.1093/cid/ciw326]
39. Bassetti M, Peghin M, Vena A. Challenges and solution of invasive aspergillosis in non-neutropenic patients: a review. Infect Dis Ther. 2018;7(1):17-27. [Link] [DOI:10.1007/s40121-017-0183-9]
40. Mühlemann K, Wenger C, Zenhäusern R, Täuber MG. Risk factors for invasive aspergillosis in neutropenic patients with hematologic malignancies. Leukemia. 2005;19(4):545-50. [Link] [DOI:10.1038/sj.leu.2403674]
41. Baddley JW, Stroud TP, Salzman D, Pappas PG. Invasive mold infections in allogeneic bone marrow transplant recipients. Clin Infect Dis. 2001;32(9):1319-24. [Link] [DOI:10.1086/319985]
42. Mohammadi R, Foroughifar E. Candida infections among neutropenic patients. Caspian J Intern Med. 2016;7(2):71-7. [Link]
43. Sipsas NV, Bodey GP, Kontoyiannis DP. Perspectives for the management of febrile neutropenic patients with cancer in the 21st century. Cancer. 2005;103(6):1103-13. [Link] [DOI:10.1002/cncr.20890]
44. Walsh TJ, Gamaletsou MN. Treatment of fungal disease in the setting of neutropenia. Hematol Am Soc Hematol Educat Prog. 2013;2013(1):423-7. [Link] [DOI:10.1182/asheducation-2013.1.423]